Skip to content

AIM round-up: Ovoca Bio, Kore Potash, Kropz


That soaring oil price hit equity markets across the board today and AIM was no exception, with the index reaching the bell thirteen and a half points lower, although significantly up from intraday lows.

  • Ovoca Bio +32%
  • Kore Potash +29%
  • Kropz +26%
  • Mysale Group -54%
  • Diurnal -19%

Ovoca Bio [LON:OVB] added 32% on the day after a note published this morning detailing its business exposure to Russia. The share price was rattled a few weeks back but has now regained that lost ground. The stock is however relatively thinly traded and did close on a spread of some 27% tonight, so it’s difficult to read too much into this.

Kore Potash LON:KP2 also fared well, adding 29% by the bell. The stock did find a degree of speculative support a few days back, but this proved to be rather short lived, resulting in a retreat ahead of the weekend. Today’s renewed move does however push the shares close to levels not seen for a year, with significantly elevated trade levels also being seen.

A notable mention for Kropz LON:KRPZ where we saw speculative gains last week and a further 26% has been tacked on today. This morning the company announced news of a further equity draw down, which strengthens the position of the major shareholder. That’s arguably going to limit free float but could also serve to pave the way for a buy out.

Mysale Group LON:MYSL is back in focus, off some 54% on the day. The stock took a pummelling off the back of last month’s trading update and in a day of very thin trading stepped lower yet again, although this was backed off by a very wide spread.

Diurnal LON:DNL also struggled, slipping 19% by the bell. An update from the Scottish Medicines Consortium has a negative outcome on the ability for one of its drugs to be prescribed. This is set to directly impact the company’s sales forecasts for the UK as a wider number of healthcare commissioning groups take direction from the SMC. However roll outs across Europe should still leave the company on track for 100% sales growth for the year to 30th June.

Looking for great investing ideas? Sign up to our free newsletter.

Join us on WhatsApp

This article does not constitute investment advice. Make sure you do your own research or consult a professional advisor.

'How to' Guides

Our latest in-depth company reports

Detailed reviews of selected companies and investment trusts.

On the podcast

Sign up for great investing stock tips

Thanks to our Site Partners

Our partners are established, regulated businesses and we are grateful for their support.

CME Group
FP Markets

Back To Top